According to the present invention there is provided a sensitive quantitative assay for the determination of a hapten "X" which comprises: preparing a conjugate of the hapten X which conjugate is adapted to ellicit antibody formation, and injecting a mammal with said conjugate, resulting in a specific antibody against the said hapten, "anti-X"; preparing a conjugate of the hapten X and of another entity Y, which is either another hapten or a larger molecule, injecting a mammal with the entity Y if it is a larger molecule, or with a conjugate thereof if it is a small molecule which does not by itself ellicit antibody formation, so as to form anti-Y antibodies, preparing a conjugate of a suitable enzyme and the antibody against Y, i.e. an (enzyme)-(anti-Y)-conjugate; adsorbing the antibodies against X, i.e. anti-X on a solid support, contacting said solid support with a mixture containing the unknown quantity of hapten X and a known quantity of the X-Y conjugate; removing unreacted X and X-Y, leaving all anti-X sites occupied, adding enzyme-labelled anti-Y antibody; adding a suitable substrate resulting in a color reacting and measuring the intensity of color indicating the quantity of bound enzyme and deducing from calibration curves the quantity of the hapten X; and to a kit for carrying out such assay.
The invention relates to a process for the production of pharmaceutical preparations based on 5-aminosalicylic acid in which the 5-aminosalicylic acid is mixed with physiologically and toxicologically acceptable, basic auxiliaries and/or buffer mixtures, which in a 1% aqueous solution give pH-values in the range from 8 to 12, and the mixture obtained is processed in known manner to form tablets, film tablets, dragees, capsules or suppositories, or in which the 5-aminosalicylic acid is mixed with a concentrated aqueous solution of the above-mentioned basic auxiliaries and/or buffer mixtures, the 5-aminosalicylic acid salt formed is precipitated, separated off from the aqueous solution and dried and the salt obtained is processed in known manner to form tablets, film tablets, dragees, capsules or suppositories.
A buffer composition for use in the electrophoretic separation of proteins into fractions, the buffer composition consisting essentially of Tris; an acid having the formula R.sub.1 --CO--NH--R.sub.2 --COOH where R.sub.1 is NH.sub.2 or an alkyl or aryl group, preferably NH.sub.2 , C.sub.6 H.sub.5 or C.sub.6 H.sub.4 NH.sub.2 and where R.sub.2 is an alkyl group, preferably CH.sub.2, CH.sub.2 --CH.sub.2 or CH(CH.sub.3); and a water soluble salt of the acid; the acid and salt being present in amounts and in a ratio to maintain the pH of an aqueous solution of the composition at from 8.2 to 9.0. The preferred acid is hippuric acid.
A buffer composition for use in the electrophoretic separation of proteins into fractions, the buffer composition consisting essentially of Tris; an acid having the formula R.sub.1 --CO--NH--R.sub.2 --COOH where R.sub.1 is NH.sub.2 or an alkyl or aryl group, preferably NH.sub.2, C.sub.6 H.sub.5 or C.sub.6 H.sub.4 NH.sub.2 and where R.sub.2 is an alkyl group, preferably CH.sub.2, CH.sub.2 --CH.sub.2 or CH(CH.sub.3); and a water soluble salt of the acid; the acid and salt being present in amounts and in a ratio to maintain the pH of an aqueous solution of the composition at from 8.2 to 9.0. The preferred acid is hippuric acid.
The invention relates to a process for the production of pharmaceutical preparations based on 5-aminosalicylic acid in which the 5-aminosalicylic acid is mixed with physiologically and toxicologically acceptable, basic auxiliaries and/or buffer mixtures, which in a 1% aqueous solution give pH-values in the range from 8 to 12, and the mixture obtained is processed in known manner to form tablets, film tablets, dragees, capsules or suppositories, or in which the 5-aminosalicylic acid is mixed with a concentrated aqueous solution of the above-mentioned basic auxiliaries and/or buffer mixtures, the 5-aminosalicylic acid salt formed is precipitated, separated off from the aqueous solution and dried and the salt obtained is processed in known manner to form tablets, film tablets, dragees, capsules or suppositories.
The present invention provides a process for the detection of an analyte, wherein a sample containing the analyte is incubated either with a labelled binding partner and the immobilized analyte or an immobilized analyte analogue or with the labelled analyte or analyte analogue and an immobilized binding partner, the binding partner displaying towards the immobilized or labelled analyte or analyte analogue a higher affinity than towards the free analyte, and the labelled binding partner or the labelled analyte or the labelled analyte analogue is present in insufficiency compared with the concentration of the analyte to be detected. The present invention also provides an agent for carrying out this process, wherein it contains either the immobilized analyte or an immobilized analyte analogue and a labelled binding partner or the labelled analyte or a labelled analyte analogue and an immobilized binding partner, as well as optionally an appropriate buffer system and further conventionally used adjuvants, the binding partner displaying towards the immobilized or labelled analyte or analyte analogue a higher affinity than towards the free analyte.
